Search Results
May 27, 2026, 02:28 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
patient and graft survival at one year.In patients treated with Idefirix, at one year, mean estimated glomerular filtration rate (eGFR) was 52.4 mL/min/1.73 m², graft survival was 92%, and patient survival was 98%.The study was well conducted with patient retention greater than 94%. Idefirix
More news about: Hansa Biopharma AB
May 27, 2026, 02:25 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
patient and graft survival at one year.In patients treated with Idefirix, at one year, mean estimated glomerular filtration rate (eGFR) was 52.4 mL/min/1.73 m², graft survival was 92%, and patient survival was 98%.The study was well conducted with patient retention greater than 94%. Idefirix
More news about: Hansa Biopharma AB
May 26, 2026, 11:34 ET Riverside Research Executives Named 2026 Washington Exec Chief Officer Awards Finalists
multidisciplinary research and development and encourages collaboration. Riverside Research's areas of expertise include Object and Activity Detection; Accelerated AI/ML; Zero Trust; Open Architectures; Computational Electromagnetics; Plasma Physics; Precision Timing; Terahertz Imaging; Commercial Intelligence, Surveillance,
More news about: RIVERSIDE RESEARCH
May 26, 2026, 11:03 ET Freedom Collection Just Got an Upgrade
KAYALI is introducing new 50ml & 100ml sizes, giving its community even more to spray, layer, and love.
More news about: KAYALI
May 26, 2026, 10:06 ET AI-Enabled Cyberespionage Is a National Security Threat. Integrated Cyber Solutions Has an Answer
attacks during the message-encoding stage, the sampling phase of the QS7001 Quantum Shield secure microcontroller (which embeds NIST-approved ML-KEM/Kyber and ML-DSA/Dilithium algorithms in silicon), and a commercial pipeline that management now describes as exceeding US$200 million for the 2026–2029 period
More news about: Equity Insider
May 22, 2026, 21:12 ET Lupin erhält Zulassung in China für Oseltamivirphosphat-Suspension zum Einnehmen
Oseltamivirphosphat-Suspension zum Einnehmen, 6 mg/ml, wird eingeführt und vermarktet, um den Zugang zu erweitern, insbesondere für die pädiatrische Anwendung. Damit baut Lupin seine globale Präsenz aus
More news about: Lupin Limited
May 22, 2026, 21:10 ET Lupin reçoit l'approbation de la Chine pour la suspension orale de phosphate d'oseltamivir
Le phosphate d'oseltamivir pour suspension orale, 6 mg/mL, sera lancé et commercialisé afin d'en élargir l'accès, en particulier pour un usage pédiatrique. Lupin renforce ainsi sa présence mondiale et son engagement
More news about: Lupin Limited
May 22, 2026, 12:43 ET ESENTIA schließt die Emission von Investment-Grade-Anleihen im Wert von 2 Milliarden US-Dollar ab und erhält für seine erste Unternehmensanleihe gleichzeitig ein Rating von drei Ratingagenturen
-im-wert-von-2-milliarden-us-dollar-ab-und-erhalt-fur-seine-erste-unternehmensanleihe-gleichzeitig-ein-rating-von-drei-ratingagenturen-302780323.html
More news about: Esentia
May 22, 2026, 12:38 ET ESENTIA conclut une offre d'obligations de premier ordre de 2 milliards de dollars, obtenant dans le même temps la notation des trois principales agences sur les premières obligations d'entreprise
2-milliards-de-dollars-obtenant-dans-le-meme-temps-la-notation-des-trois-principales-agences-sur-les-premieres-obligations-dentreprise-302780321.html
More news about: Esentia
May 22, 2026, 12:13 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
6 mg/mL will be launched and commercialized to expand access, particularly for pediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated:
More news about: Lupin Pharmaceuticals, Inc.
May 22, 2026, 10:00 ET Lupin recibe la aprobación en China para la suspensión oral de fosfato de oseltamivir
6 mg/ml para ampliar el acceso, especialmente para uso pediátrico. Esto expande la presencia global de Lupin y reafirma su compromiso de brindar medicamentos asequibles y de alta calidad a pacientes y niños que los necesitan.El fosfato de oseltamivir para suspensión oral, 6 mg (base)/mL, está
More news about: Lupin Limited
May 22, 2026, 07:06 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated:
More news about: Lupin Limited
May 22, 2026, 07:00 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated:
More news about: Lupin Limited
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
severe renal impairment (CLcr <30 mL/min), end stage renal disease, or in patients on dialysis is unknown. No dosage adjustments are necessary in patients with mild or moderate hepatic (Child-Pugh A or B) and/or renal impairment (CLcr ≥30-89 mL/min).Please see full
More news about: Eli Lilly and Company
May 21, 2026, 13:37 ET RADIN Health and AZmed Elevate Radiology Workflow with AZtrauma's Expanded FDA-Cleared AI Capabilities
efficiency, productivity, and scalability of hospitals, imaging centers and radiology practices. Utilizing artificial intelligence (AI), machine learning (ML), and natural language processing (NLP), RADIN offers a Cloud-based, Serverless, All-In-One RIS, PACS, Dictation AI®, and Select®
More news about: Radin LLC
May 21, 2026, 11:00 ET Vectra AI Named a Leader in the 2026 Gartner® Magic Quadrant™ for Network Detection and Response
post-compromise network detection and response becomes essential to modern defense models.Vectra AI has long addressed this challenge by applying AI/ML to network data, analyzing how attackers behave across hybrid networks spanning on-premises, multi-cloud, SaaS, identity, edge, and IoT/OT infrastructure.
More news about: Vectra AI
May 21, 2026, 09:00 ET OSULLOC Introduces Matcha Plus: A Functional Matcha Line Designed for Modern Wellness
wellness goals. Each product also features natural fruit flavor infusions and comes in a convenient single-serve stick pouch format. Simply add to 500ml of cold water or sparkling water, shake, and enjoy — no whisk or preparation required. With 10 sticks per box, Matcha Plus is designed to fit seamlessly
More news about: OSULLOC
May 21, 2026, 09:00 ET ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Submitted Incomplete Disclosures: SueWallSt
d-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-submitted-incomplete-disclosures-suewallst-302778421.htmlSOURCE SueWallSt.com
More news about: SueWallSt.com
May 21, 2026, 08:32 ET PaddleTechPro LLC Launches JOOLAREPAIR: The 3-Second Pickleball Paddle Restoration Spray That Brings Back Factory Spin and Grip
paddles."Formulated for all paddle brands and materials—carbon fiber, fiberglass, and composite surfaces—JOOLAREPAIR, is safe, fast, and easy to apply. The 425ml (220g) bottle delivers consistent coverage for repeated use.Official launch is scheduled for June 2026, with early access invitations extended
More news about: PaddleTechPro LLC
May 21, 2026, 08:07 ET Induction Therapies Unveils GloXO+PDRN: Advanced Microneedling Recovery Treatment for Post Procedure Care
and I'll be using it more in our treatment protocols."The formula also includes Sodium Hyaluronate and SolubleCollagen and is packaged in a 5 mL single treatment applicator, giving providers a precise way to integrate regenerative support directly into the service.For more information about
More news about: Collagen P.I.N.
May 21, 2026, 08:00 ET Oracle Fusion Data Intelligence Helps Organizations Across the World Accelerate AI-Driven Decision-Making
and implemented Oracle Fusion Data Intelligence for ERP and HCM to deliver ready-to-use analytics, governed access to sensitive data, and embedded AI/ML capabilities."Oracle Fusion Data Intelligence lets us go beyond just the numbers by combining revenue and passenger data to provide meaningful
More news about: Oracle
May 21, 2026, 00:01 ET Powered by Silicon Labs, Comminent Ships 500,000 Wi-SUN Modules
solutions that are device agnostic and built to provide high reliability. The company's state-of-the-art device management platform is powered by AI/ML tools combined with edge-computing technologies to ensure faster decision-making and trigger control actions based on predefined policies. Comminent
More news about: Silicon Labs
May 20, 2026, 11:15 ET Sinch Named a leader in the 2026 Gartner® Magic Quadrant™ for Communications Platform as a Service
ecosystem of more than 1,000 active partners and 500+ integrations spanning Salesforce, Microsoft, SAP, Adobe, and AI-native platforms; advanced AI and ML-driven fraud controls, including identity verification capabilities accessible via MCP for use directly within autonomous agent workflows; and a global
More news about: Sinch AB
May 20, 2026, 11:13 ET Sinch Named a leader in the 2026 Gartner® Magic Quadrant™ for Communications Platform as a Service
ecosystem of more than 1,000 active partners and 500+ integrations spanning Salesforce, Microsoft, SAP, Adobe, and AI-native platforms; advanced AI and ML-driven fraud controls, including identity verification capabilities accessible via MCP for use directly within autonomous agent workflows;
More news about: Sinch AB
May 20, 2026, 10:00 ET UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)
24979-126-190.4 mL vials 30-count
More news about: Upsher-Smith Laboratories, LLC